GlaxoSmithKline Pharmaceuticals share news, announcements and annual reports
NSE: GLAXOBSE: 500660Pharmaceuticals & BiotechnologyMid Cap
GlaxoSmithKline Pharmaceuticals Limited · Formerly Glaxo (India) · Face value ₹10 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed Jan 1969 on BSE, Dec 2000 on NSE
Last close ₹2,494.30down ₹20.80 (0.83%)BSE ₹2,483.55
Share price at the NSE close on 30 Oct 2026. Previous close ₹2,515.10.
30 Oct: open ₹2,527.60, high ₹2,528.90, low ₹2,479.30
52-week range of traded prices to 30 Oct 2026
₹2,088.10Low, 12 Jun 2026₹3,120.70High, 28 Aug 2026
- Next results date: the board meets on 3 Nov 2026 to consider: financial results. The notice · Results calendar
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹42,255 Cr221st largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 39.56
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 18.64
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 2.29%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 50.6%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 56.3%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- 0.00
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 56,34965.0% delivered
GlaxoSmithKline Pharmaceuticals disputes and clarifications
34 filed, newest first.
Aug 2026
6 Aug · Legal
Jun 2026
25 Jun · Legal
Mar 2026
31 Mar · Legal
24 Mar · Legal
7 Mar · Legal
Feb 2026
28 Feb · Legal
23 Feb · Legal
Jan 2026
1 Jan · Legal
Dec 2025
31 Dec · Legal
31 Dec · Legal
The exchange asked on 30 Dec 2025
22 Dec · Legal
18 Dec · Legal
Aug 2025
5 Aug · Legal
Jun 2025
27 Jun · Legal
19 Jun · Legal
May 2025
Apr 2025
24 Apr · Legal
Significant increase in volume has been observed in GlaxoSmithKline Pharmaceuticals Limited. The Exchange, in order to ensure that investors have latest relevant information about the company and to inform the market place so that the interest of the investors is safeguarded, has written to the company. The response from the company is awaited.11 Apr · Legal
Feb 2025
28 Feb · Legal
28 Feb · Legal
11 Feb · Legal
5 Feb · Legal
5 Feb · Legal
Jan 2025
Dec 2024
4 Dec · Legal
Exchange has sought clarification from GlaxoSmithKline Pharmaceuticals Limited for the quarter ended 30-Sep-2024 with respect to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company is required to clarify the following: -1. Financial results submitted is not as per format prescribed under Schedule III of the Companies Act, 2013. -2. Limited Review Report/ Independent Auditor's Report is not in the format prescribed by SEBI The response of the Company is awaited.
Oct 2024
16 Oct · Legal
Nov 2021
26 Nov · Legal
The exchange asked on 25 Nov 2021
Aug 2021
4 Aug · Legal
The exchange asked on 3 Aug 2021
Jul 2018
26 Jul · Legal
Exchange has sought clarification from GlaxoSmithKline Pharmaceuticals Limited with respect to announcement dated 24-Jul-2018, regarding " GlaxoSmithKline Pharmaceuticals Limited has informed the Exchange that a meeting of the Board of Directors of the Company was held July 24, 2017 has approved and recommended a bonus issue of one equity share for every equity share held as on a record date to be determined. The bonus issue of equity shares will be subject to approval by the shareholders, and any other applicable statutory and regulatory approvals. The Bonus shares once allotted shall rank pari-passu in all respects and carry the same rights as the existing Equity Shares and shall be entitled to participate in full in any dividend and other corporate action, recommended and declared after the new equity shares are allotted.". On basis of above the Company is required to clarify following: 1. Reason for change viz. appointment, resignation, removal, death or otherwise; The response of the Company is awaited.
Sep 2016
19 Sep · Legal
The exchange asked on 16 Sep 2016
Jun 2015
8 Jun · Legal
Exchange has sought clarification from GlaxoSmithKline Pharmaceuticals Limited with respect to recent news item captioned "CCI slaps Rs. 64cr fine on GlaxoSmithKline, Sanofi". In this regard, Exchange have advised the Company to provide clarification/confirmation on the news item in detail including the following: a) Whether such event/negotiations/article stated in published news were taking place? If so, you are advised to provide the said information along with the sequence of events in chronological order and the material impact of this article on the Company. b) Whether company are aware of any information that has not been announced to the Exchanges under clause 36 of the Listing Agreement. The response from the Company is awaited.
Dec 2014
24 Dec · Legal
Exchange had sought clarification from GlaxoSmithKline Pharmaceuticals Limited with respect to a news item captioned "CCI Gives Approval for Novartis-GSK Pharma Deal". The Company has clarified that "The Competition Commission of India has approved the GSK - Novartis deal relates to the global deal between GlaxoSmithKline Plc ( GSK Plc ) and Novartis AG ( Novartis ). GSK Plc, an entity situated in UK indirectly holds shares of GlaxoSmithKline Pharmaceuticals Limited ( GSK India ) and GSK India has not accepted any binding commitments in relation to the global deal. No filings and / or representations have been made by GSK India in the application for the approval filed by GSK Plc and Novartis. GSK India shall make all necessary disclosures as and when any obligation to do so arises under clause 36 of the listing agreement".24 Dec · Legal
Exchange has sought clarification from GlaxoSmithKline Pharmaceuticals Limited with respect to recent news item captioned "CCI Gives Approval for Novartis-GSK Pharma Deal". In this regard, Exchange have advised the Company to provide clarification/confirmation on the news item in detail including the following: a) Whether such event/negotiations/article stated in published news were taking place? If so, you are advised to provide the said information along with the sequence of events in chronological order and the material impact of this article on the Company. b) Whether company are aware of any information that has not been announced to the Exchanges under clause 36 of the Listing Agreement. The response from the Company is awaited.